Inici › Càncer de pulmó › Michigan › Lansing
Assaigs clínics de Càncer de pulmó a Lansing, MI
11 estudis de Càncer de pulmó busquen participants en centres de Lansing i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
ReclutantFase 3
- University of Michigan Health - Sparrow Lansing, Lansing
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ReclutantEstudi observacionalVoluntaris sans benvinguts
- University of Michigan Health - Sparrow Lansing, Lansing
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
ReclutantFase 3
- University of Michigan Health - Sparrow Lansing, Lansing
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
ReclutantFase 3
- University of Michigan Health - Sparrow Lansing, Lansing
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
ReclutantFase 3
- University of Michigan Health - Sparrow Lansing, Lansing
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
ReclutantFase 3
- Karmanos Cancer Institute at McLaren Greater Lansing, Lansing
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
ReclutantFase 3
- Karmanos Cancer Institute at McLaren Greater Lansing, Lansing
- University of Michigan Health - Sparrow Lansing, Lansing
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
ReclutantFase 2
- University of Michigan Health - Sparrow Lansing, Lansing
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
ReclutantFase 2
- University of Michigan Health - Sparrow Lansing, Lansing
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
ReclutantFase 2/3
- University of Michigan Health - Sparrow Lansing, Lansing
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutantEstudi observacional
- Massive Bio SYNERGY-AI site, Lansing
Assaigs de Càncer de pulmó en altres ciutats
- Houston, TX78 estudis
- Boston, MA62 estudis
- New York City, NY60 estudis
- Los Angeles, CA45 estudis
- Washington, DC41 estudis
- Arlington, VA41 estudis
- Chicago, IL41 estudis
- Nashville, TN40 estudis
- Baltimore, MD40 estudis
- St. Louis, MO39 estudis
- Columbus, OH37 estudis
- Philadelphia, PA36 estudis
Altres estudis a Lansing
- Càncer de pròstata10 estudis
- Càncer de mama10 estudis
- Càncer de pulmó de cèl·lules no petites9 estudis
- Càncer (tots els tipus)6 estudis
- Càncer de laringe5 estudis
- Càncer de bufeta5 estudis
- Trastorns de somnolència excessiva5 estudis
- Càncer colorrectal4 estudis
- Càncer de ronyó (carcinoma de cèl·lules renals)4 estudis
- Càncer de còlon4 estudis
- Carcinoma urotelial (de cèl·lules de transició)4 estudis
- Carcinoma de cèl·lules escamoses de cap i coll4 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.